HK1187615A1 - 吡咯並六元雜芳環類衍生物、其製備方法及其在醫藥上的應用 - Google Patents
吡咯並六元雜芳環類衍生物、其製備方法及其在醫藥上的應用Info
- Publication number
- HK1187615A1 HK1187615A1 HK14100596.2A HK14100596A HK1187615A1 HK 1187615 A1 HK1187615 A1 HK 1187615A1 HK 14100596 A HK14100596 A HK 14100596A HK 1187615 A1 HK1187615 A1 HK 1187615A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrole
- preparation
- membered heteroaryl
- heteroaryl ring
- method therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110434071 | 2011-12-21 | ||
PCT/CN2012/086922 WO2013091539A1 (zh) | 2011-12-21 | 2012-12-19 | 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1187615A1 true HK1187615A1 (zh) | 2014-04-11 |
Family
ID=48667710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14100596.2A HK1187615A1 (zh) | 2011-12-21 | 2014-01-20 | 吡咯並六元雜芳環類衍生物、其製備方法及其在醫藥上的應用 |
Country Status (23)
Country | Link |
---|---|
US (3) | US9527851B2 (zh) |
EP (1) | EP2796460B1 (zh) |
JP (1) | JP6075736B2 (zh) |
KR (1) | KR102032934B1 (zh) |
CN (1) | CN103415520B8 (zh) |
AU (1) | AU2012357296B2 (zh) |
BR (1) | BR112014014325B1 (zh) |
CA (1) | CA2857977C (zh) |
CY (1) | CY1121161T1 (zh) |
DK (1) | DK2796460T3 (zh) |
ES (1) | ES2682755T3 (zh) |
HK (1) | HK1187615A1 (zh) |
HR (1) | HRP20181201T1 (zh) |
HU (1) | HUE039111T2 (zh) |
LT (1) | LT2796460T (zh) |
MX (1) | MX358679B (zh) |
PL (1) | PL2796460T3 (zh) |
PT (1) | PT2796460T (zh) |
RS (1) | RS57621B1 (zh) |
RU (1) | RU2618673C2 (zh) |
SI (1) | SI2796460T1 (zh) |
TW (1) | TWI601728B (zh) |
WO (1) | WO2013091539A1 (zh) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014KN02993A (zh) * | 2012-07-17 | 2015-05-08 | Glaxosmithkline Ip No 2 Ltd | |
EP3290421B1 (en) * | 2013-02-22 | 2019-01-02 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
US9422300B2 (en) * | 2013-06-07 | 2016-08-23 | Jiangsu Hengrui Medicine Co., Ltd. | Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor |
EP3461827B1 (en) | 2013-09-26 | 2022-02-23 | Cadent Therapeutics, Inc. | Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b |
PE20161246A1 (es) | 2013-12-05 | 2016-11-25 | Pfizer | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo |
KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
CN105566327A (zh) | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
ES2754548T3 (es) * | 2014-11-05 | 2020-04-20 | Jiangsu Hengrui Medicine Co | Forma cristalina de bisulfato inhibidor de quinasa JAK y un método de preparación del mismo |
CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
PL3305788T3 (pl) * | 2015-05-29 | 2021-03-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Inhibitor kinazy janusowej |
JP6875407B2 (ja) * | 2016-02-19 | 2021-05-26 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
CN108884100B (zh) * | 2016-11-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 吡咯并六元杂芳环类衍生物的制备方法及中间体 |
US20200095241A1 (en) | 2016-12-22 | 2020-03-26 | Bayer Cropscience Aktiengesellschaft | Substituted 1,2,4-thiadiazolylpyrrolones and 1,2,4-thiadiazolylhydantoins and salts thereof and use thereof as herbicides |
MX2019007374A (es) | 2016-12-22 | 2019-09-18 | Bayer Cropscience Ag | Heteroarilpirrolonas sustituidas y sus sales y su uso como ingredientes activos herbicidas. |
WO2018133823A1 (zh) * | 2017-01-20 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法 |
CN109843872B (zh) * | 2017-09-20 | 2022-08-30 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
WO2019096303A1 (zh) | 2017-11-20 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | 一种局部给药的药物组合物及其制备方法 |
BR112020012166A2 (pt) | 2017-12-19 | 2020-11-24 | Bayer Aktiengesellschaft | n-heterociclil- e n-heteroaril-tetra-hidropirimidinonas substituídas e os sais das mesmas, e o uso das mesmas como substâncias ativas herbicidas |
EP3768272A4 (en) * | 2018-03-21 | 2021-08-11 | Xibin Liao | JAK INHIBITORS |
TWI754170B (zh) * | 2018-09-12 | 2022-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Jak激酶抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 |
US20210379052A1 (en) * | 2018-09-27 | 2021-12-09 | Shenzhen Chipscreen Biosciences Co., Ltd. | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity |
CA3118488A1 (en) * | 2018-11-05 | 2020-05-14 | Avista Pharma Solutions, Inc. | Chemical compounds |
CN111205290B (zh) * | 2018-11-22 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的结晶形式及其制备方法 |
CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
JP7248256B2 (ja) | 2019-03-14 | 2023-03-29 | 上海華匯拓医薬科技有限公司 | Jakキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用 |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
AU2020338043A1 (en) * | 2019-08-26 | 2022-03-31 | Chemwerth, Inc. | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021115286A1 (zh) * | 2019-12-10 | 2021-06-17 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP2023068213A (ja) * | 2020-03-31 | 2023-05-17 | 慶應義塾 | 炎症性腸疾患処置剤、及び、アミド化合物又はその塩 |
WO2021201126A1 (ja) * | 2020-03-31 | 2021-10-07 | 富士フイルム株式会社 | アミド化合物又はその塩、医薬組成物、及び、ヒストン脱アセチル化酵素阻害剤 |
CN113698404B (zh) * | 2020-05-21 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种低溶剂残留的六氢环戊并[c]吡咯-2(1H)-甲酰胺化合物及其制备方法 |
CA3183916A1 (en) | 2020-07-28 | 2022-02-03 | Arcutis Biotherapeutics, Inc. | Laureth-4 containing topical formulations |
US20220133728A1 (en) | 2020-10-29 | 2022-05-05 | Arcutis Biotherapeutics, Inc. | Methods for treating vitiligo lesions having improved efficacy |
AU2021383606A1 (en) | 2020-11-17 | 2023-06-29 | Arcutis Biotherapeutics, Inc. | Compositions and methods for deep dermal drug delivery |
CN114591321A (zh) * | 2020-12-04 | 2022-06-07 | 广州费米子科技有限责任公司 | 氮杂并环化合物、其制备方法及其用途 |
CN116761628A (zh) * | 2020-12-11 | 2023-09-15 | 江苏恒瑞医药股份有限公司 | Jak抑制剂在肾脏疾病中的应用 |
CN112933095A (zh) * | 2020-12-29 | 2021-06-11 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
WO2023016551A1 (zh) * | 2021-08-12 | 2023-02-16 | 江苏恒瑞医药股份有限公司 | 用于治疗或预防抗宿主病的吡咯并六元杂芳物 |
WO2023029943A1 (zh) * | 2021-09-03 | 2023-03-09 | 星药科技(北京)有限公司 | 一种芳杂环化合物及其制备方法和用途 |
US20230181591A1 (en) | 2021-12-15 | 2023-06-15 | Arcutis Biotherapeutics, Inc. | Stable formulations of shr0302 |
WO2023151069A1 (zh) * | 2022-02-14 | 2023-08-17 | 湖南南新制药股份有限公司 | 吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途 |
WO2024114814A1 (en) * | 2022-12-02 | 2024-06-06 | Onquality Pharmaceuticals China Ltd | Jak inhibitors, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0278659A (ja) * | 1988-09-12 | 1990-03-19 | Shionogi & Co Ltd | アザビシクロアルカン類化合物 |
US5521193A (en) | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
US5527910A (en) * | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
PT1087970E (pt) * | 1998-06-19 | 2004-06-30 | Pfizer Prod Inc | Compostos pirrolo¬2,3-d|pirimidina |
SI1235830T1 (en) | 1999-12-10 | 2004-06-30 | Pfizer Products Inc. | PYRROLO(2,3-d)PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
JP4811978B2 (ja) * | 2000-01-24 | 2011-11-09 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 3−アミノキナゾリン−2,4−ジオン抗菌剤 |
YU83302A (sh) * | 2000-06-26 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi |
WO2004087142A1 (en) * | 2003-04-04 | 2004-10-14 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
GB0307856D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
CA2525945A1 (en) | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7381738B2 (en) * | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
EP1778688A1 (en) * | 2004-07-22 | 2007-05-02 | Glaxo Group Limited | Antibacterial agents |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
EP1831216A2 (en) * | 2004-12-23 | 2007-09-12 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
US8633205B2 (en) * | 2005-02-03 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
EP2211620B1 (en) * | 2007-10-25 | 2013-12-25 | Merck Sharp & Dohme Corp. | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES |
EP2246347B1 (en) | 2008-01-23 | 2016-09-28 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Dicycloazaalkane derivates, preparation processes and medical uses thereof |
TW200944523A (en) * | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
EP2419408A4 (en) * | 2009-04-16 | 2012-09-05 | Msd Kk | INDOLE SUBSTITUTED DERIVATIVE IN POSITION 3 BY ARYL OR HETEROARYLE |
TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
WO2012058645A1 (en) * | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
EP2686321B1 (en) * | 2011-03-17 | 2016-11-16 | Bristol-Myers Squibb Company | Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
EP2721025B1 (en) * | 2011-06-16 | 2015-11-25 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
-
2012
- 2012-12-19 HU HUE12859120A patent/HUE039111T2/hu unknown
- 2012-12-19 PT PT12859120T patent/PT2796460T/pt unknown
- 2012-12-19 US US14/365,497 patent/US9527851B2/en active Active
- 2012-12-19 DK DK12859120.3T patent/DK2796460T3/en active
- 2012-12-19 CA CA2857977A patent/CA2857977C/en active Active
- 2012-12-19 RS RS20180887A patent/RS57621B1/sr unknown
- 2012-12-19 PL PL12859120T patent/PL2796460T3/pl unknown
- 2012-12-19 BR BR112014014325-0A patent/BR112014014325B1/pt active IP Right Grant
- 2012-12-19 LT LTEP12859120.3T patent/LT2796460T/lt unknown
- 2012-12-19 KR KR1020147017839A patent/KR102032934B1/ko active IP Right Grant
- 2012-12-19 MX MX2014007033A patent/MX358679B/es active IP Right Grant
- 2012-12-19 ES ES12859120.3T patent/ES2682755T3/es active Active
- 2012-12-19 RU RU2014128307A patent/RU2618673C2/ru active
- 2012-12-19 JP JP2014547698A patent/JP6075736B2/ja active Active
- 2012-12-19 EP EP12859120.3A patent/EP2796460B1/en active Active
- 2012-12-19 WO PCT/CN2012/086922 patent/WO2013091539A1/zh active Application Filing
- 2012-12-19 SI SI201231364T patent/SI2796460T1/sl unknown
- 2012-12-19 CN CN201280011688.2A patent/CN103415520B8/zh active Active
- 2012-12-19 AU AU2012357296A patent/AU2012357296B2/en active Active
- 2012-12-20 TW TW101148623A patent/TWI601728B/zh active
-
2014
- 2014-01-20 HK HK14100596.2A patent/HK1187615A1/zh unknown
-
2016
- 2016-11-01 US US15/340,081 patent/US20170044171A1/en not_active Abandoned
-
2018
- 2018-03-22 US US15/933,371 patent/US10428074B2/en active Active
- 2018-07-27 HR HRP20181201TT patent/HRP20181201T1/hr unknown
- 2018-10-03 CY CY20181101020T patent/CY1121161T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181201T1 (hr) | Derivat šestočlanog heteroaril prstena pirola, proces za njihovu pripremu i medicinsku uporabu | |
ZA201503753B (en) | Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof | |
EP2842935A4 (en) | MANNICH-BASE, MANUFACTURING METHOD AND APPLICATION THEREOF | |
ZA201404625B (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
IL231386A0 (en) | Pyrazoloquinolinone derivatives, their preparation and medical use | |
EP2746283A4 (en) | PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES | |
PL2562172T3 (pl) | Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania | |
EP2763998A4 (en) | TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF | |
ZA201400188B (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
EP2786982A4 (en) | AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
IL223721A0 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
EP2924042A4 (en) | BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
EP2671878A4 (en) | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | |
IL233238A (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
EP2700642A4 (en) | CAMPTOTHECIN COMPOUND CONTAINING 7-ELEMENT STABLE LACTONE CORE, METHOD OF MANUFACTURE AND USE | |
IL248698A0 (en) | History of 1-h-pyrrolidine-4,2-dione and processes for their preparation | |
ZA201309559B (en) | Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof | |
EP2742946A4 (en) | PROCESS FOR THE PRODUCTION OF PYROSTEGIA VENUSTA DERIVATIVES, PYROSTEGIA VENUSTA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
EP2805956A4 (en) | GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | |
EP2634184A4 (en) | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | |
EP2690085A4 (en) | NORBORNENE ESTER DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USES THEREOF | |
EP2610257A4 (en) | DIIMIDED DERIVATIVE OF BERBAMINE, MANUFACTURING METHOD AND ITS USE | |
EP2626347A4 (en) | DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF | |
HK1198539A1 (zh) | 種甾醇類衍生物、其製備方法及用途 | |
EP2786989A4 (en) | 2-ALKYL OR ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, METHOD OF MANUFACTURING THEREOF AND THE APPLICATION THEREOF |